Projects

The BeYond-COVID project aims to make COVID-19 data accessible to scientists in laboratories but also to anyone who can use it, such as medical staff in hospitals or government officials. Going beyond SARS-CoV-2 data, the project will provide a framework for making data from other infectious diseases open and accessible to everyone.

c4c (conect4children) is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population.

The canSERV project aims to defragment the landscape of European cancer research and will enable academia and industry access to cross-cutting services and support from basic science up to clinical translation to foster personalised medicine for cancer patients. The project will contribute to the EU Cancer Mission through the provision of innovative services.

CoMeCT is ensuring enhanced European clinical research preparedness and response capacity to infectious disease (ID) outbreaks with epidemic potential through sustained strategic and scientific coordination of adaptive platform trials and cohort studies. Uniting existing coordination initiatives into a single coherent coordination mechanism for adaptive platform trials and cohort studies.

The ECRAID-Base (European Clinical Research Alliance for Infectious Diseases) project follows the successful ECRAID-Plan project which defined the business model of the ECRAID network. This pan-European network will generate rigorous evidence to improve diagnosis, prevention and treatment of infections and to better respond to emerging infectious disease threats.

ECRAID-PRIME, a European Adaptive Platform Trial (APT) of COVID-19 therapeutics in primary care will build on many years of EU investment in infrastructure for primary care trials and a mature primary care research network that has pioneered novel, efficient, platform clinical trial designs.

The central aim of the project is to enable clinical and quality of care assessment research using data extracted directly from electronic health records (EHR) of emergency departments (ED). 

The programme will establish a comprehensive strategy covering funding, research, data, training, tools and clinical aspects to increase the efficiency of results use, diagnosis, drug discovery, patient care and to empowering all stakeholders.

The EOSC Future project is the major implementation project building the European Open Science Cloud (EOSC). Putting together expertise from major European research infrastructures (computing, network, storage, data, tools) the project is working on operationalising the EOSC. It also builds on previous EC-funded projects that developed core components of this platform. The architecture connects and integrates existing and new technological elements. It brings in relevant data content and tools to investigate and analyse. This is carried out by a large consortium of over 90 European partners, in collaboration with researchers and important European stakeholders.

EOSC-ENTRUST aims to create a European network of Trusted Research Environments (TRE) for sensitive data and to drive European interoperability by joint development of a common blueprint for federated data access and analysis to support the development of the European Open Science Cloud (EOSC).

EOSC4Cancer will make diverse types of cancer data accessible: genomics, imaging, medical, clinical, environmental and socio-economic. It will use and enhance federated and interoperable systems for securely identifying, sharing, processing and reusing FAIR data across borders and offer them via community-driven analysis environments.

This Partnership brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing European public health needs. The EU-funded ERA4Health Partnership brings together 32 entities and 27 funding organisations from 21 countries, with the common goal of fostering high-impact translational research for addressing public health needs.

The ERIC Forum 2 project is intended to strengthen and support the implementation of the ERIC Regulation and ERIC services, to structure their cooperation and sustainability across Europe, and to consolidate the integration of the ERICs into the European Research Area by deepening the ERIC Forum’s contribution to research policies. 

The EU-Africa PerMed project aims to integrate organizations from the African continent into ICPerMed activities, as a means to contribute to the implementation of personalised medicine (PM) in the global context, fostering joint PM projects and programmes between Europe and Africa, and strengthening bilateral EU-Africa Union science, technology and innovation in health.

EU-RESPONSE aims to design and run a new adaptive European platform trial on COVID-19 and emerging infectious diseases. EU-RESPONSE will allow the European expansion of the DisCoVeRy study, a phase III, open-label, adaptive, randomized, controlled, multi-centre clinical trial designed to evaluate the safety and efficacy of medicinal products in hospitalized adult patients diagnosed with COVID-19. The DisCoVeRy trial was originally initiated in France as WHO Solidarity trial “add-on” study and thanks to EU-RESPONSE it will further expand to many other European countries.

EuroGCT is here to help make sense of gene and cell therapy - from science in the lab to treatments for patients. The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT) brings together 47 partner organisations and institutions across Europe with a goal of providing reliable and accessible information about the use of cells and genetic material to treat disease.

The INTEGRATE-LMedC project aims to develop a new concept to guide and support decision-making for the next-generation research infrastructure (RI) to facilitate efficient utilization and harmonization of large medical cohorts (LMedC), and to accelerate scientific and medical breakthroughs in Europe and beyond.

The overall aim of INVENTS is to provide clinical trial stakeholders, trialists and regulators with a generalisable framework encompassing methods, workflows and evidence-tools to improve the level of evidence in regulatory decision making in rare diseases. This will be achieved through the development and validation of improved extrapolation models, simulation and in silico trials, model based clinical trial design and evidence synthesis methods, all based on robust and mature computational models and qualified on extensive data from representative selected use cases.

ISIDORe will contribute to Europe’s readiness to any epidemic-prone pathogen through a global, integrated and preparedness-driven approach by providing free of charge access to cutting-edge resources and services to scientific user communities for supporting their research projects in the field of infectious diseases in “peaceful times” as well as during outbreaks or epidemics

QUANTUM aims to develop and implement a label mechanism that will attest to the quality and utility of data as well as the maturity level of the providers' data quality procedures, and which could ideally be adopted as part of future HealthData@EU.

The project kicks off with the ambition of establishing a European research and innovation eco-system that facilitates fast and cost-effective patient-centric development and access to repurposed medicines.

The SIMCor project aims to develop an in-silico platform and simulation tools for the development, validation and regulatory approval of cardiovascular devices, providing tangible value to patients and clinicians, device manufacturers, clinical researchers, medical authorities and regulatory bodies. It will focus on two clinically and economically relevant cardiovascular procedures and devices, transcatheter aortic valve implantation (TAVI) and pulmonary artery pressure sensors (PAPS), and will extrapolate best practices for in-silico trials that will be translated into Standard Operating Procedures (SOPs) for all cardiovascular device manufacturing and clinical communities.

The TBMED (A testing bed for the development of high-risk medical devices) project will establish an open innovation testing bed specialised in the development of high-risk devices (≥Class IIb).

With TESA III, 15 institutions from 9 African and 3 European countries come together to strengthen and enhance the capacities for clinical research in Southern Africa built during TESA, and to strengthen the collaboration of North-South and South-South networking activities among its members.

VACCELERATE will accelerate phase 2 & 3 COVID-19 vaccine trials. VACCELERATE brings together the different stakeholders involved in vaccine development across the continent to develop a platform for trial design and conduct. VACCELERATE will include capacity mapping to identify suitable sites as well as capacity building through the creation of dedicated training. Volunteer registries and access to laboratory sites are also provided within the framework of the project. The project will also ensure the harmonisation of data collection, open data sharing and pooling of data for more robust analysis and data standardisation.